These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26802647)

  • 1. Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
    Seubwai W; Vaeteewoottacharn K; Kraiklang R; Umezawa K; Okada S; Wongkham S
    Oncol Res; 2016 Jan; 23(1-2):21-8. PubMed ID: 26802647
    [TBL] [Abstract][Full Text] [Related]  

  • 2.  Thymosin β10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma.
    Sribenja S; Natthasirikul N; Vaeteewoottacharn K; Sawanyawisuth K; Wongkham C; Jearanaikoon P; Wongkham S
    Ann Hepatol; 2016; 15(4):577-85. PubMed ID: 27236157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy.
    Seubwai W; Wongkham C; Puapairoj A; Khuntikeo N; Pugkhem A; Hahnvajanawong C; Chaiyagool J; Umezawa K; Okada S; Wongkham S
    PLoS One; 2014; 9(8):e106056. PubMed ID: 25170898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
    Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
    Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
    Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
    Ramos PMM; Pezuk JA; Castro-Gamero AM; Oliveira HF; Scrideli CA; Umezawa K; Tone LG
    Anticancer Agents Med Chem; 2018; 18(4):541-549. PubMed ID: 29141555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ.
    Katsman A; Umezawa K; Bonavida B
    Curr Pharm Des; 2009; 15(7):792-808. PubMed ID: 19275643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
    Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
    Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
    Srijiwangsa P; Ponnikorn S; Na-Bangchang K
    BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A; Umezawa K; Bonavida B
    Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
    Dabaghmanesh N; Matsubara A; Miyake A; Nakano K; Ishida T; Katano H; Horie R; Umezawa K; Watanabe T
    Cancer Sci; 2009 Apr; 100(4):737-46. PubMed ID: 19469019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
    Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
    World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
    Meng Z; Mitsutake N; Nakashima M; Starenki D; Matsuse M; Takakura S; Namba H; Saenko V; Umezawa K; Ohtsuru A; Yamashita S
    Endocrinology; 2008 Nov; 149(11):5357-65. PubMed ID: 18653704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
    Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R
    Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
    Zeekpudsa P; Kukongviriyapan V; Senggunprai L; Sripa B; Prawan A
    J Exp Clin Cancer Res; 2014 Jan; 33(1):11. PubMed ID: 24460787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer.
    Kozakai N; Kikuchi E; Hasegawa M; Suzuki E; Ide H; Miyajima A; Horiguchi Y; Nakashima J; Umezawa K; Shigematsu N; Oya M
    Br J Cancer; 2012 Aug; 107(4):652-7. PubMed ID: 22805327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
    Sato M; Nakanishi K; Haga S; Fujiyoshi M; Baba M; Mino K; ; Niwa H; Yokoo H; Umezawa K; Ohmiya Y; Kamiyama T; Todo S; Taketomi A; Ozaki M
    Oncol Res; 2013; 21(6):333-43. PubMed ID: 25198663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.